

CORPORATE NEWS

Successful start into the new fiscal year

One-time effect contributes significantly to the very strong sales

- Revenues with € 5.5 million 36 % above prior year
- Including one-time effect of € 1.8 million from the sale of MeVisLab usage rights
- Earnings before interest and taxes (EBIT) of € 2.9 million
(significantly above prior-year's figure of € 0.9 million)
- EBIT margin of 52 %
- Net profit after taxes increased by € 0.7 million to € 4.4 million

Bremen, February 21, 2017 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its figures for the first quarter of fiscal year 2017, with the reporting period October 1 to December 31, 2016.

Sales generated in the first quarter of 2017 amounted to € 5.5 million, 36 % higher than the corresponding quarter of the previous year (€ 4.1 million). The increase in sales resulted mainly from the sale of extensive usage rights for the tool for the development of software prototypes MeVisLab for € 1.8 million, which is also included in the revenues of the Other Diagnostics segment. Sales of new licenses fell by 29 % to € 1.3 million and the maintenance business decreased by 5 %. Sales in the Digital Mammography segment decreased by 15 % to € 2.7 million (prev. year: € 3.1 million), sales in the Other Diagnostics segment increased to € 2.9 million (prev. year: € 1.0 million), without the one-time effect this corresponds to a growth of 11 %.

The reduction in personnel expenses by -13 % to € 1.8 million (prev. year: € 2.0 million) was mainly attributable to provisions for special payments in the previous year. Operating costs fell significantly in the first quarter of 2017; other operating expenses decreased in the first quarter compared to the same quarter last year to € 0.5 million (prev. year: € 0.8 million), mainly due to the provision recognized in the previous year for litigation costs.

This results in an EBIT (earnings before interest and taxes) of € 2.9 million compared to € 0.9 million in the prior-year period. At 52 %, the EBIT margin more than doubled compared to prior-year's figure.

The financial result significantly improved compared to the previous year with now € 1.6 million. This was mainly due to the effects of the development of US\$ in connection with a high proportion of US dollars in the available liquidity.

Due to the fiscal unity, which became effective as of January 1, 2016, the tax result consists solely of the withholding tax of € 13 k. After-tax earnings consequently rose to € 4.4 million, which is equivalent to undiluted earnings per share of €2.43 (prev. year: €2.07).

The Annual General Meeting will take place on March 8, 2017. The interim financial statement for the first half year 2017 will be published on May 18, 2017.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.